KR20070108909A - 알데스류킨과 함께 사용하는 항혈관형성제 - Google Patents

알데스류킨과 함께 사용하는 항혈관형성제 Download PDF

Info

Publication number
KR20070108909A
KR20070108909A KR1020077021118A KR20077021118A KR20070108909A KR 20070108909 A KR20070108909 A KR 20070108909A KR 1020077021118 A KR1020077021118 A KR 1020077021118A KR 20077021118 A KR20077021118 A KR 20077021118A KR 20070108909 A KR20070108909 A KR 20070108909A
Authority
KR
South Korea
Prior art keywords
ril
amine
cells
administered
phenyl
Prior art date
Application number
KR1020077021118A
Other languages
English (en)
Korean (ko)
Inventor
샤론 리아 오커먼
킴벌리 데니스-마이즈
로렌스 엘리아스
바히자 잘랄
다니엘 메네지스
게리 더블류. 위더렐
Original Assignee
노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 filed Critical 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드
Publication of KR20070108909A publication Critical patent/KR20070108909A/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020077021118A 2005-02-18 2006-02-17 알데스류킨과 함께 사용하는 항혈관형성제 KR20070108909A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65434105P 2005-02-18 2005-02-18
US60/654,341 2005-02-18

Publications (1)

Publication Number Publication Date
KR20070108909A true KR20070108909A (ko) 2007-11-13

Family

ID=36569884

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077021118A KR20070108909A (ko) 2005-02-18 2006-02-17 알데스류킨과 함께 사용하는 항혈관형성제

Country Status (10)

Country Link
EP (1) EP1853302A2 (zh)
JP (1) JP2008530239A (zh)
KR (1) KR20070108909A (zh)
CN (1) CN101146549A (zh)
AU (1) AU2006214138A1 (zh)
BR (1) BRPI0608880A2 (zh)
CA (1) CA2598448A1 (zh)
MX (1) MX2007010037A (zh)
RU (1) RU2007134570A (zh)
WO (1) WO2006089150A2 (zh)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101497607B (zh) * 2008-01-29 2012-11-28 上海百灵医药科技有限公司 舒尼替尼的合成方法
EP2149565A1 (de) * 2008-07-24 2010-02-03 Bayer Schering Pharma AG Sulfonsubstituierte Chinazolinderivate als Immunmodulatoren zur Behandlung von enzündlichen und allergischen Erkrankungen
US9045453B2 (en) 2008-11-14 2015-06-02 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
EA020117B1 (ru) * 2008-11-14 2014-08-29 Консерт Фармасьютикалс Инк. Замещенные диоксопиперидинилфталимидные производные
EP3575288B1 (en) 2009-09-03 2021-10-27 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
WO2012079075A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Deuterated phthalimide derivatives
WO2013130849A1 (en) 2012-02-29 2013-09-06 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
EP2838879A1 (en) 2012-04-20 2015-02-25 Concert Pharmaceuticals Inc. Deuterated rigosertib
US9145411B2 (en) 2012-08-02 2015-09-29 Asana Biosciences, Llc Substituted amino-pyrimidine derivatives
WO2014066243A1 (en) 2012-10-22 2014-05-01 Concert Pharmaceuticals, Inc. Solid forms of {s-3-(4-amino-1-oxo-isoindolin-2yl)(piperidine-3,4,4,5,5-d5)-2,6-dione}
WO2014110322A2 (en) 2013-01-11 2014-07-17 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
WO2014127214A1 (en) 2013-02-15 2014-08-21 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9353123B2 (en) 2013-02-20 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
WO2014170910A1 (en) 2013-04-04 2014-10-23 Natco Pharma Limited Process for the preparation of lapatinib
WO2015066482A1 (en) 2013-11-01 2015-05-07 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
KR101478925B1 (ko) 2013-12-31 2015-01-08 아주대학교산학협력단 프로테아좀 저해제와 로페라마이드를 유효성분으로 함유하는 암질환 예방 또는 치료용 약학조성물
KR20190051010A (ko) 2016-09-08 2019-05-14 칼라 파마슈티컬스, 인크. 치료 화합물의 결정형 및 그의 용도
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509423A4 (en) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
CN108069913B (zh) * 2016-11-18 2022-03-01 陕西师范大学 双(吗啉基烷氧基)喹唑啉衍生物及其在抗肿瘤方面的用途
AU2019381688A1 (en) 2018-11-13 2021-06-03 Biotheryx, Inc. Substituted isoindolinones
CN114920704B (zh) * 2019-07-26 2023-11-03 暨南大学 一种苯基哌嗪喹唑啉类化合物或其药学上可接受的盐、制法与用途
CN111499583B (zh) * 2020-05-22 2022-02-15 沈阳工业大学 喹唑啉衍生物及其作为抗肿瘤药物的应用
CN112538071A (zh) * 2020-11-30 2021-03-23 新乡医学院第一附属医院 用作raf-1抑制剂的化合物、制备方法和用途

Also Published As

Publication number Publication date
WO2006089150A3 (en) 2006-11-02
MX2007010037A (es) 2008-02-15
AU2006214138A1 (en) 2006-08-24
WO2006089150A2 (en) 2006-08-24
EP1853302A2 (en) 2007-11-14
JP2008530239A (ja) 2008-08-07
BRPI0608880A2 (pt) 2010-02-02
RU2007134570A (ru) 2009-03-27
CA2598448A1 (en) 2006-08-24
CN101146549A (zh) 2008-03-19

Similar Documents

Publication Publication Date Title
KR20070108909A (ko) 알데스류킨과 함께 사용하는 항혈관형성제
CN110996952A (zh) 用于治疗癌症的方法
AU2006313491B2 (en) Compositions and methods for treating thrombocytopenia
Pirrotta et al. Targeted-therapy in advanced renal cell carcinoma
US10314834B2 (en) Therapeutic agent or treatment method for Philadelphia chromosome-positive (Ph+) acute lymphocytic leukemia (ALL) having IKZF1 mutation
RU2630975C2 (ru) Режим дозирования pi-3 киназы
JP5576290B2 (ja) 白血病の管理における３−（インドリル）−または３−（アザインドリル）−４−アリールマレイミド誘導体の用途
TWI741286B (zh) 治療癌症之方法
RU2304436C2 (ru) Применение производных n-фенил-2-пиримидинамина против основывающихся на мастоцитах заболеваний, подобных аллергическим нарушениям
KR20220011651A (ko) Gapdh를 억제하기 위한 방법 및 조성물
JP2019528250A (ja) Ｂｃｌ−２阻害剤とｍｃｌ−１阻害剤との組み合わせ、その使用及び医薬組成物
US20220008409A1 (en) Cancer combination therapy using quinoline carboxamide derivative
TW202313050A (zh) 組合療法
Sabbah et al. RTK Inhibitors in Melanoma: From Bench to Bedside. Cancers 2021, 13, 1685
Kulasekararaj et al. The Non-transplant Treatment of Myelodysplastic Syndromes—What's on the Horizon?
WO2023242107A1 (en) Novel ras inhibitors
TW202404600A (zh) 使用ptpn11抑制劑及pd-1/pd-l1抑制劑之組合療法
WO2023242101A1 (en) Novel ras inhibitors
WO2023242102A1 (en) Novel ras inhibitors
WO2023242106A1 (en) Novel ras inhibitors
WO2023242104A1 (en) Diaminoacridine derivatives as inhibitors of ras
TW202404599A (zh) 使用經取代之嘧啶-4(3h)-酮及納武單抗(nivolumab)之組合療法
WO2023242103A1 (en) Novel ras inhibitors
WO2023242100A1 (en) Novel ras inhibitors
WO2023242097A1 (en) Mitoxanthrone derivatives as ras inhibitors

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid